Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a schizophrenia drug tame stubborn high blood pressure?

NCT ID NCT07090161

Disease control Sponsor: Vanda Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether iloperidone, a drug already used for schizophrenia, can help lower blood pressure in people whose hypertension is not controlled by their current medications. About 240 adults will receive either iloperidone or a placebo for 4 weeks, and researchers will measure changes in systolic blood pressure. The goal is to see if this drug can be a safe and effective add-on treatment for uncontrolled hypertension.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
iloperidone (Fanapt)
What this could lead to
If it works, this could offer a new add-on treatment option for people whose high blood pressure is not controlled by current medications.
What could go wrong
This is an early Phase 2 trial with only 240 participants, so results may not apply to everyone. Iloperidone is already approved for other uses, but its safety and effectiveness for hypertension are not yet proven.
Why investors are watching

Vanda Pharmaceuticals is running a Phase 2 trial testing iloperidone, a drug already used for schizophrenia, as a treatment for uncontrolled hypertension. For a small company, this readout matters because it could expand the drug's use into a much larger patient population, changing the company's revenue base beyond its current products.

If it works: If the trial shows iloperidone safely lowers blood pressure in people not controlled by current treatments, Vanda could seek approval for a new indication. That would give the company a second major product and access to a large market of patients with hypertension.

If it fails: Phase 2 trials fail often, and this drug was not originally developed for blood pressure, so the chance of a negative result is real. If the trial fails or is delayed, Vanda loses time and money, and its stock could suffer because the company would remain dependent on its existing drugs.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * SiSBP \>/= 130 mmHg despite \>8 weeks treatment w/ 1 or more antihypertensive therapies Exclusion Criteria: * Confirmed Grade 3/severe hypertension (SiSBP \>/= 180 mmHg, SiDBP \>/= 120 mmHg), unstable cardiac disease, renal insufficiency

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension Uncontrolled hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    28 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Vanda Investigative Site

    NOT_YET_RECRUITING

    Phoenix, Arizona, 85053, United States

  • Vanda Investigative Site

    RECRUITING

    Tempe, Arizona, 85281, United States

  • Vanda Investigative Site

    NOT_YET_RECRUITING

    Tucson, Arizona, 85715, United States

  • Vanda Investigative Site

    RECRUITING

    Chula Vista, California, 91910, United States

  • Vanda Investigative Site

    RECRUITING

    Dublin, California, 94568, United States

  • Vanda Investigative Site

    NOT_YET_RECRUITING

    Valencia, California, 91355, United States

  • Vanda Investigative Site

    RECRUITING

    Walnut Creek, California, 94596, United States

  • Vanda Investigative Site

    NOT_YET_RECRUITING

    Doral, Florida, 33172, United States

  • Vanda Investigative Site

    RECRUITING

    Fort Myers, Florida, 33912, United States

  • Vanda Investigative Site

    RECRUITING

    Columbus, Georgia, 31904, United States

  • Vanda Investigative Site

    RECRUITING

    Oak Brook, Illinois, 60523, United States

  • Vanda Investigative Site

    RECRUITING

    Tinley Park, Illinois, 60477, United States

  • Vanda Investigative Site

    RECRUITING

    El Dorado, Kansas, 67042, United States

  • Vanda Investigative Site

    RECRUITING

    Wichita, Kansas, 67226, United States

  • Vanda Investigative Site

    RECRUITING

    Lexington, Kentucky, 40509, United States

  • Vanda Investigative Site

    RECRUITING

    Hazelwood, Missouri, 63042, United States

  • Vanda Investigative Site

    NOT_YET_RECRUITING

    Las Vegas, Nevada, 89119, United States

  • Vanda Investigative Site

    NOT_YET_RECRUITING

    Mount Kisco, New York, 10549, United States

  • Vanda Investigative Site

    NOT_YET_RECRUITING

    Rochester, New York, 14609, United States

  • Vanda Investigative Site

    RECRUITING

    Kinston, North Carolina, 28501, United States

  • Vanda Investigative Site

    RECRUITING

    Cincinnati, Ohio, 45212, United States

  • Vanda Investigative Site

    RECRUITING

    Norman, Oklahoma, 73069, United States

  • Vanda Investigative Site

    NOT_YET_RECRUITING

    Oklahoma City, Oklahoma, 73112, United States

  • Vanda Investigative Site

    RECRUITING

    Charleston, South Carolina, 29414, United States

  • Vanda Investigative Site

    NOT_YET_RECRUITING

    Carrollton, Texas, 75006, United States

  • Vanda Investigative Site

    NOT_YET_RECRUITING

    Salt Lake City, Utah, 84124, United States

  • Vanda Investigative Site

    RECRUITING

    Burke, Virginia, 22015, United States

  • Vanda Investigative Site

    RECRUITING

    Norfolk, Virginia, 23502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.